Orphalan Acquires Orphelia Pharma to Strengthen Rare Disease Portfolio in Pediatric Neurology and Oncology
Key Insights
Orphalan has acquired Orphelia Pharma, a company specializing in rare and severe pediatric diseases in neurology and oncology, strengthening its position as a European leader in rare diseases.
The acquisition expands Orphalan's capabilities in rare neurological and oncological pediatric diseases while improving access to medicines for children and adults with rare conditions.
Orphelia Pharma brings one authorized medicine in the European Union (Kigabeq®) and a second under regulatory review (Kizfizo®) to the combined platform.
Orphalan, an international pharmaceutical company specializing in orphan drug development and commercialization, has acquired Orphelia Pharma, a Paris and Lyon-based company focused on treating rare and severe pediatric diseases, particularly in neurology and oncology. The strategic transaction, announced December 12, 2025, strengthens Orphalan's position as a European leader with a global commercial footprint in rare diseases.
Strategic Expansion in Pediatric Rare Diseases
The acquisition significantly expands Orphalan's therapeutic portfolio and capabilities in rare neurological and oncological pediatric diseases. The combined entity aims to provide greater reach and improved access to medicines for children and adults with rare conditions through a unique platform that combines scientific excellence, agility, and global commercialization.
"The acquisition of Orphelia Pharma reinforces our mission: to provide innovative and accessible treatments to patients living with rare diseases, wherever they are," said Dr. Naseem Amin, Chief Executive Officer of Orphalan. "Together, we are building a unique platform that brings together scientific excellence, agility, international development and commercial capabilities to advance care for patients of all ages suffering from orphan diseases."
Enhanced Product Portfolio and Pipeline
Orphelia Pharma contributes significant assets to the acquisition, including one authorized medicine in the European Union, Kigabeq®, and a second treatment, Kizfizo®, currently under regulatory review. The company has established regional distribution agreements across Europe and other regions and maintains collaborations with academic and industrial partners to advance research in rare diseases.
Dr. Hugues Bienayméé, Founder and Deputy Chief Executive Officer of Orphelia Pharma, emphasized the potential for accelerated impact: "At Orphelia Pharma, we have dedicated ourselves to developing safe and effective pediatric medicines that address major unmet medical needs in rare diseases. Joining Orphalan will allow us to increase the impact of our treatments and make them available more rapidly to the children who need them most."
Established Market Presence
Orphalan brings substantial commercial experience to the combined entity, having been founded in 2011 through a collaboration with AGEPS (search) and Hôpital Lariboisière (search). The company developed Cuprior®, a treatment for Wilson's disease (search), which is now authorized in 38 countries and marketed in 28. Orphalan's shareholders include Bpifrance (search), Advent (search), and the management team.
The company's established ambition focuses on reducing diagnostic delays and making innovative orphan drugs accessible to as many patients as possible through a patient-centered approach and close collaboration with healthcare professionals.
Future Outlook for Rare Disease Treatment
Gilles Alberici, Chief Executive Officer of Orphelia Pharma, highlighted the broader significance of the merger: "Bringing together our two complementary companies marks an important milestone, both for our organizations and for the broader community of patients living with rare diseases."
The acquisition positions the combined companies to accelerate innovation and improve access to transformative treatments for patients worldwide. Both organizations have committed to ensuring continuity of care and supporting their partners and patients throughout the integration process.